Vaccitech plc (VACC): Price and Financial Metrics
VACC Price/Volume Stats
Current price | $5.00 | 52-week high | $5.10 |
Prev. close | $4.49 | 52-week low | $1.64 |
Day low | $4.28 | Volume | 165,300 |
Day high | $5.10 | Avg. volume | 244,643 |
50-day MA | $2.94 | Dividend yield | N/A |
200-day MA | $2.59 | Market Cap | 192.74M |
VACC Stock Price Chart Interactive Chart >
Vaccitech plc (VACC) Company Bio
Vaccitech plc is a clinical-stage biopharmaceutical company that engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. Its therapeutic programs include VTP-300, indicated for the treatment of chronic hepatitis B infection; VTP-200, indicated for the treatment of human papilloma virus infection; VTP-850, indicated for the treatment of prostate cancer; and VTP-600, indicated for the treatment of non-small cell lung cancer. The company's prophylactic programs include VTP-400 for the prevention of herpes zoster or shingles; and VTP-500 for the prevention of Middle East respiratory syndrome. In addition, it is developing AZD1222, a COVID-19 vaccine. Vaccitech plc was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc on March 31, 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, United Kingdom.
Latest VACC News From Around the Web
Below are the latest news stories about VACCITECH PLC that investors may wish to consider to help them evaluate VACC as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start off the week with a breakdown of the biggest pre-market stock movers that investors need to know about for Monday! |
Kymera Therapeutics, Inc. (KYMR) Soars 14.3%: Is Further Upside Left in the Stock?Kymera Therapeutics, Inc. (KYMR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
Vaccitech plc (NASDAQ:VACC) surges 85%; individual investors who own 44% shares profited along with institutionsKey Insights Significant control over Vaccitech by individual investors implies that the general public has more power... |
Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023OXFORD, United Kingdom, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced it will host a Key Opinion Leader (KOL) Webinar to discuss the current treatment landscape for people living with chronic Hepatitis B Virus (HBV) infection and po |
Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate DevelopmentsOXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced its financial results for the second quarter of 2023 and provided an overview of the Company’s progress. “In the second quarter of 2023, Vaccitech achieved importa |
VACC Price Returns
1-mo | N/A |
3-mo | N/A |
6-mo | N/A |
1-year | 103.67% |
3-year | -67.45% |
5-year | N/A |
YTD | N/A |
2023 | 0.00% |
2022 | -78.85% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...